Applied Bioscience International Inc. named Robert F.Amundsen chief financial officer and John H. Timoney seniorvice president. Timoney has been with the company since itsinception and has been given special responsibility for investorrelations. Amundsen was chief financial officer of Pharmaco,with which ABI merged earlier this year. Applied Bioscience ofEast Millstone, N.J., conducts biological safety testing andagrichemical research.

Oculon Corp. named William L. Matier vice president of drugdevelopment and clinical affairs. He was senior vice presidentof research and development at Givaudan Corp., a division ofHoffmann-La Roche. In addition, the Cambridge, Mass.,company named to its board of directors William C. Hulley, anassociate at Fostin Capital Corp., and Frederick R. Blume,founder and managing partner of Capital Health VenturePartners. Privately held Oculon is developing products for thediagnosis and treatment of cataracts based on novel phaseseparation technology.

Calgene Fresh Inc. of Davis, Calif., named James Gerecke vicepresident of retail sales and Cynthia M. Seik vice president offood service sales. Gerecke was national sales manager of LandO'Lakes and Seik was executive vice president of contract salesat Richelieu Group Inc. CFI, a wholly owned subsidiary ofCalgene Inc., was formed in January to develop, distribute andsell fresh produce.

Biodynamics International Inc. named Thomas A. Martin vicepresident of finance and chief financial officer and appointedDouglass C. Watson vice president of marketing and planning.Martin held the same positions at U.S. Videotel and Watson wasvice president of business development for Biodynamics. TheTampa, Fla., company provides specialty surgical products.

John J. Booth, chief financial officer of Incstar Corp., was namedsenior vice president. The Stillwater, Minn., companymanufactures and distributes immunodiagnostic products forhealth care professionals and manufacturers.

Somatix Therapy Corp. named Michael Sofroniew to the newlyappointed position of neural program director. He was alecturer with the University of Cambridge, England. TheAlameda, Calif., company is focused on the genetic modificationof selected human cells to enable the production and deliveryof therapeutic substances.

British Bio-technology Group plc. named Andrew Millardirector of clinical research. He was European director ofclinical research for Marion Merrell Dow. British-Bio-technologyof Oxford, England, is working on an AIDS vaccine and an anti-cancer drug.

James T. O'Brien, former president and chief operating officerof Elan Corp. plc, was named to the board of directors ofCarrington Laboratories Inc. of Irving, Texas. Carrington isfocused on carbohydrate-based therapeutics for treating life-threatening illnesses and the dressing and management ofwounds.

(c) 1997 American Health Consultants. All rights reserved.

No Comments